ASX Announcements

First patent in Israel granted for trofinetide
Change of Director's Interest Notice
New international institutional shareholder acquires 14% of Neuren
Change of Director's Interest Notice
Temporary pause in new enrolments for LAVENDER trial in US
Trading Halt
Neuren to capture substantially greater value after Phase 3
Additional information
Compelling results for NNZ-2591 dose ranging study in Phelan-McDermid syndrome model
Commentary on potential benefit to Neuren of RPD designation